Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revision Previous revision
home:diseases:cancer [03.13.2019]
sallieq [Recent research]
home:diseases:cancer [03.13.2019] (current)
sallieq [H]
Line 203: Line 203:
 Note also that the primary ARBs being evaluated, candesartan and telmisartan,​ have significantly different actions than olmesartan. According to the //in silico// emulations of Dr. Marshall, they are VDR antagonists. Note also that the primary ARBs being evaluated, candesartan and telmisartan,​ have significantly different actions than olmesartan. According to the //in silico// emulations of Dr. Marshall, they are VDR antagonists.
  
-==== ====+==== Risk ====
  
 <​blockquote>​analyses found no evidence that cancer risk increased with increasing duration of ARB exposure (RR increase per year=0.99) <​blockquote>​analyses found no evidence that cancer risk increased with increasing duration of ARB exposure (RR increase per year=0.99)
home/diseases/cancer.txt · Last modified: 03.13.2019 by sallieq
© 2015, Autoimmunity Research Foundation. All Rights Reserved.